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Abstract
Background: Malawi introduced an ambitious public health program known as “Option B+” which provides all
HIV-infected pregnant and breastfeeding women with lifelong combination antiretroviral therapy, regardless of
WHO clinical stage or CD4 cell count. The PMTCT Uptake and REtention (PURE) study aimed at evaluating the effect
of peer-support on care-seeking and retention in care.
Methods/design: PURE Malawi was a three-arm cluster randomized controlled trial that compared facility-based
and community-based models of peer support to standard of care under Option B+ strategy. Each arm was
expected to enroll a minimum of 360 women with a total minimum sample size of 1080 participants. 21 sites
(clusters) were selected for inclusion in the study. This paper describes the site selection, recruitment, enrollment
process and baseline characteristics of study sites and women enrolled in the trial.
Results: Study implementation was managed by 3 partner organizations; each responsible for 7 study sites. The
trial was conducted in the South East, South West, and Central West zones of Malawi, the zones where the
implementing partners operate. Study sites included 2 district hospitals, 2 mission hospitals, 2 rural hospitals, 13
health centers and 1 private clinic. Enrollment occurred from November 2013 to November 2014, over a median
period of 31 weeks (range 17–51) by site. A total of 1269 HIV-infected pregnant (1094) and breastfeeding (175)
women, who were eligible to initiate ART under Option B+, were enrolled. Each site reached or surpassed the
minimum sample size. Comparing the number of women enrolled versus antenatal cohort reports, sites recruited a
median of 90% (IQR 75–100) of eligible reported women. In the majority of sites the ratio of pregnant and lactating
women enrolled in the study was similar to the ratio of reported pregnant and lactating women starting ART in the
same sites. The median age of all women was 27 (IQR 22–31) years. All women have ≥20 months of possible
follow-up time; 96% ≥ 2 years (24–32 months).
Conclusion: The PURE Malawi study showed that 3 implementing partner organizations could successfully recruit a
complex cohort of pregnant and lactating women across 3 geographical zones in Malawi within a reasonable timeline.
Trial registration: This study is registered at clinicaltrials.gov - ID Number NCT02005835. Registered 4 December, 2013.
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Plain english summary
Malawi introduced a new strategy that aims at prevent-
ing HIV infection from mother to child. There is no cure
for HIV, but medication (antiretroviral treatment) is
available to slow the progression of the virus and help
prevent transmission of HIV to others. The so called
“Option B+” strategy means that all HIV-infected preg-
nant and breastfeeding women start antiretroviral treat-
ment as soon as they are diagnosed. The PMTCT
Uptake and REtention (PURE) study evaluated whether
support provided by peers (mothers who are HIV-
infected and on treatment themselves) can help to
increase the number of HIV-infected pregnant and
breastfeeding women to start treatment (uptake) and
keep them in care and on treatment (retention). The
study took place in 21 health facilities, where mothers
either received no peer support (7 sites), peer support in
the facility (7 sites) or peer support in the community
(7 sites). This article describes how the study was suc-
cessfully set up and managed by 3 organizations. Between
November 2013 and November 2014, a total of 1269 HIV-
infected women were included in the study in the 21
health facilities. We describe that it is possible to set up a
complex study across 3 geographical zones in Malawi.
Background
In 2011, Malawi introduced an ambitious public health
strategy known as “Option B+”, providing a standardized
lifelong combination antiretroviral therapy (ART) regi-
men to all HIV-infected pregnant and breastfeeding
women, irrespective of their CD4 cell count or World
Health Organisation (WHO) clinical stage of HIV infec-
tion. This public health approach for the prevention of
mother to child transmission (PMTCT) of HIV has since
been adopted by several other countries in the region
and was included in the updated WHO guidelines in
2013 [1]. Initial data have demonstrated that the Option
B+ strategy has resulted in large increases in the number
of pregnant women accessing PMTCT [2]. However,
concerns have been raised about the level of attrition of
women from care [3]. Although the strategy offers an at-
tractive rapid ART scale-up and has the potential to pro-
foundly impact maternal and infant outcomes, services
supporting the implementation of Option B + have not
been formally evaluated. Several issues were identified at
the national level as potential threats to the successful
implementation and scale up of the strategy: a) potential
suboptimal uptake of ART by asymptomatic pregnant
women due to low treatment literacy and stigma; b) low
adherence to ART and poor follow-up of HIV exposed
infants; and c) lack of psycho-social support for long
term retention in this relatively asymptomatic patient
population [4]. Hence, it seemed apparent that the iden-
tification of interventions to support PMTCT uptake
and retention would be the first step towards improve-
ment. A recently published systematic review identified
9 completed studies and 5 ongoing trials which exam-
ined initiation of ART in pregnant women [5]. While the
authors report several promising interventions for
improving ART initiation, the quality of evidence was
insufficient to support recommendations. In addition, re-
sults for ART initiation in pregnant women were not inde-
pendently examined, and maternal retention in PMTCT
care and exposed infants care were not assessed.
Although randomized controlled trials are promoted
as the highest level of evidence for the evaluation of in-
terventions, the implementation of rigorous trials within
the context of the public health sector are complex and
therefore still uncommon [6]. PURE Malawi embraced
the challenge of implementing a multi-site controlled
trial within the context of public health clinics under
real world conditions in Malawi. PURE Malawi was a
three-arm cluster randomized controlled trial that aimed
at evaluating whether facility- or community-based peer-
support would enhance care-seeking and retention in
care by HIV-infected pregnant and breastfeeding
women, their HIV-exposed infants, and their male sex
partners, and ultimately improve health outcomes in all
three populations. The hypothesis was that enhanced
support for women and their families within facilities
and/or community would result in improved retention
in the continuum of PMTCT care. The primary trial out-
come is the proportion of women retained in care, 2
years after they initiated antiretroviral therapy under the
Option B+ strategy. This paper describes the site selec-
tion, recruitment, enrollment process and baseline char-
acteristics of study sites and women enrolled in the trial.
Methods
PURE Malawi was a three-arm stratified cluster random-
ized controlled trial that compared facility-based and
community-based models of peer support to standard of
care under Option B+. The three arms differed with re-
spect to the presence and location of one-on-one patient
education and support, support groups, visit reminders,
and missed visit follow-up. The trial was unblinded to
study participants and health care providers, but blinded
to outcome assessors. A comprehensive description of
the study arms was reported elsewhere [7]. The PURE
trial was managed by the PURE Malawi consortium com-
prising of governmental, non-governmental, research, and
academic partners. The consortium was led by Lighthouse
Trust. Dignitas International, The University of Malawi
College of Medicine Malaria Alert Centre, and University
of North Carolina Project were each responsible for trial
implementation in one Malawian zone. The trial was con-
ducted in the South East, South West, and Central West
zones of Malawi, the zones where the implementing
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partners operate. Selection and responsibilities of all con-
sortium members were described elsewhere [7].
Site selection and recruitment targets
Clusters (i.e. health facilities) were the unit of
randomization in this trial. Public health facilities in the
South East, South West, and Central West health zones
of Malawi, covering the central and southern geograph-
ical regions of Malawi, were assessed for eligibility in the
trial. Sites were eligible if they provided Option B+
services, did not have additional PMTCT interventions
or research activities beyond the Malawi national stand-
ard of care, and were expected to have at least 20 eligible
women for Option B+ in a 6 month period. HIV care in
Malawi is free and standardized in all public health facil-
ities. Site assessments, selection and randomization of
the sites were described elsewhere [7].
Twenty-one selected sites were stratified into 3 groups
of 7, with each group having sites of comparable size
and expected retention, based on Ministry of Health his-
toric data. Depending on the size of the health facility,
each site was expected to reach a minimum enrollment
target of 20, 50, 75, or 125 pregnant or breastfeeding
women eligible for the Option B+ program. Each arm
was expected to enroll a minimum of 360 women with a
total minimum sample size of 1080 participants. Sites
could exceed this target if they finished enrollment prior
to a 6 month period.
Enrolment process and index participants
Prior to study implementation, all Ministry of Health
staff working at ANC and ART departments in the se-
lected sites received training in study arm specific stand-
ard operating procedures, adherence to ethical standards
and management of data collection tools (Good Clinical
Practice). At each site, a PURE site coordinator was
selected to oversee the study implementation.
All newly identified HIV positive women identified
during pregnancy, delivery, or breastfeeding while seek-
ing antenatal care (ANC) or initiating ART services at
the study sites were eligible for inclusion in the study.
Women consented to participate and be followed in the
site where they had sought ANC or ART services and
were explained in which arm the site was allocated.
Based on existing PMTCT monitoring data, we antici-
pated 6 months until sample size was achieved.
All participating women were assigned a unique study
ID. Study ID stickers were placed in the study register,
the mother’s existing health passport and on all routine
clinic records for data extraction and tracking.
The index participants were newly confirmed HIV-
infected pregnant and breastfeeding women; eligible to
initiate ART under Option B+, in the 21 selected health
facilities. To attain the primary trial outcome, enrolled
women were expected to be followed until the end of the
study period (31st July 2016), transfer out, default, or death.
Data collection and management during recruitment
period
All newly identified HIV positive women were eligible
for inclusion in the study. Therefore, routinely collected
health facility cohort data prepared during quarterly
supervision visits [8] was used to compare the number
of women enrolled in the study with the number of eli-
gible women seeking care at the health facility during
the recruitment period. Monthly ANC cohort data
included the number of women newly registered, newly
diagnosed with HIV or already known HIV-infected, and
those already on ART. ART cohort data included the
number of pregnant and lactating women having started
ART per quarter.
Facility characteristics data, including availability of
HIV Testing Services (HTS), ANC and ART services
were collected by existing study personnel throughout
the enrolment period.
During study enrollment, health facility staff used
PURE registration and PURE enrolment forms to collect
data on mothers’ age, expected delivery date (pregnant
women) or date of birth of the child (lactating women),
marital status, and whether the partner lives in the
catchment area.
At the ART initiation visit, a routinely used clinical
card was initiated and treatment initiation data were re-
corded, including date, age and reason for initiation of
ART (WHO stage or pregnant/lactating), TB and KS.
The data collection and analytic methods, including a
detailed analysis plan, for the final trial outcomes were
described elsewhere [7].
Compensation of health facility for study specific
activities
During the enrolment period, each health facility re-
ceived 1000 MK (equivalent to approximately 2 USD)
per correctly enrolled study participant, in addition to a
median amount of 5000 MK per month (equivalent to
approximately 10 USD) for correct organization and
storage of clinical and study records as stipulated by the
national guidelines and PURE protocols. This amount
was shared among the facility staff involved in the study.
Results
PURE Malawi sites included 2 district hospitals, 2 mission
hospitals, 2 rural hospitals, 13 health centers and 1 private
clinic. Table 1 shows PURE Malawi sites by health zone,
implementing partner and study arm. Each implementing
partner managed the implementation of the study across
the 7 sites in the respective health zone where the partners
operate. The organization Mothers2Mothers provided
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additional support for training and implementation in all
Arm 2 sites. Table 2 shows the number of Ministry of
Health staff trained by site and cadre prior to study
implementation. Enrollment initiation varied per trial site
from November 2013 through January 2014. Recruitment
was completed in November 2014. Median enrollment
time per site was 31 weeks, ranging from 17 to 51 weeks.
Table 3 describes the number of pregnant and lactating
women enrolled per site and arm, in addition to the
number of eligible women reported in cohort reports at
ANC and ART during the recruitment period. Each site
and arm reached or surpassed the minimum sample.
However, a few participants (4%) were enrolled later than
the desired end date of July 31st 2014, making 2 years of
follow up impossible by July 31, 2016, the trial end date.
A total of 1269 women were enrolled, 1094 (86%)
pregnant and 175 (14%) lactating women.
When comparing number of enrolled pregnant women
per site with facility cohort data; 7 sites recruited >100%
of the total reported cohort of HIV-infected pregnant
women at ANC in the corresponding months. The add-
itional number of pregnant women may have started
ART, but not attended ANC in the specific study site.
Nine sites recruited >90%, 10 sites 60–90%, and 2 sites
40%–59% of the total reported cohort of pregnant
women at ANC in the corresponding months. When
comparing the number of women enrolled versus ANC
reports, sites recruited a median of 90% (IQR 75–100) of
eligible reported women from ANC.
Following quarterly ART cohort report data; in all
study sites, a total of 1934 (81%) pregnant and 454
(19%) lactating women had started ART during corre-
sponding quarters. This proportion of pregnant and
lactating women was comparable to our study sample.
Baseline characteristics of study sites
Table 4 shows the characteristic of study sites, with
regards to services available during the enrolment
period. During the enrolment period, 9 facilities experi-
enced a median of 2 weeks of HIV test kit stock outs
(range 2–8) and 13 facilities were not able to provide
HTC for a median of 4 weeks (range 1–8) due to stock
outs or unavailability of HTC providers. The 6 largest
facilities provided ANC and ART services during all
week days; in all other facilities ANC and ART services
were provided at a median of 3 days (range 2–4) and
1 day (range 1–4) per week, respectively. In 19 of the 21
facilities, ART provision was available at ANC.
Baseline characteristics of women enrolled in the trial
Cumulative baseline characteristics of women enrolled
in the trial are shown in Table 5.
The median age of all women was 27 (IQR 22–31) years,
with no difference between those pregnant and lactating.
Pregnant women were enrolled at a median of 4 months
(IQR 2–5) prenatal; breastfeeding women at a median of
5 months (IQR 1–11) postnatal. Reason for ART initiation
for all women was being pregnant or lactating (regardless
of CD4 or WHO stage). Among those with WHO stage
reported at ART initiation, 98% of both pregnant and lac-
tating women were reported clinically asymptomatic.
There was 1 documented TB case (within the last 2 years)
and 1 documented KS case at ART initiation.
Proportionally more lactating women reported being
divorced, widowed, or having no sexual partner than
pregnant women. Among women with at least one sex-
ual partner, 11% were reported not living in the same
catchment area as their partner. There was no difference
in recruitment by Health Zone period or the time for
Table 1 PURE Malawi sites by health zone, implementing partner and study arm
Implementing
partner
Central west zone South east zone South west zone
University of North Carolina Project, Lilongwe Dignitas International, Zomba Malaria Alert Centre, Blantyre
Arm 1 Daeyang Luke Hospital Publicc Mulanje District Hospitala Mwanza District Hospitala
Kasinje Health Centred Mimosa Dispensarye Chirimba Health Centred
Dr David Livingstone Memorial Clinicf
Arm 2 Lobi Rural Hospitalc Muloza Health Centred Makhetha Health Centred
Mbiza Health Centred Masenjere Health Centred
Mdeka Health Centred
Kadidi Health Centerd
Arm 3 Biriwiri Health Centred Mulanje Mission Hospitalb Trinity Mission Hospitalb
Nsipe Health Centred Mulomba Health Centred
Bilira Health Centerd Mpala Health Centred
aDistrict Hospital
bMission Hospital
cRural Hospital
dHealth Centre
eDispensary
fPrivate clinic
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follow-up between pregnant and lactating women. The
largest proportion of women was recruited between
January and July 2014, enabling 96% of women to be
followed up for at least 2 years (24–32 months) as part
of the trial.
Discussion
This paper shows that the PURE consortium was suc-
cessful in recruiting a complex cohort of pregnant and
lactating women across 3 geographical zones in Malawi.
Each site and trial arm reached or surpassed the
minimum required sample size, and the majority of sites
recruited over 90% of the reported eligible women
attending ANC during the recruitment period. Although
cluster designs are often avoided due to the challenges
of enrolling at multiple sites within a reasonable time-
line, we show that, despite the absence of remunerated
study staff within study site, only few participants were
enrolled later than the desired end date; allowing for
96% of the cohort to be followed for at least 2 years. We
report that there were HIV test kit stock outs or un-
availability of the HTC providers, which may have
prolonged the enrolment period. Shortages and stock
out of commodities at health facilities is a reality in
Malawi, however, national guidelines are set up to im-
prove the supply management [8]. In the majority of
participating sites, the ratio of pregnant and lactating
women enrolled in the study was similar to the ratio of
pregnant and lactating women initiated on ART in the
same sites. There was no difference in age between the
enrolled pregnant and lactating women. One fifth of the
women enrolled were young mothers (15–21), which is
consistent with national evaluations that describe
women in Malawi’s Option B+ program [3]. Proportion-
ally more lactating women reported being divorced,
widowed or having no sexual partner. As male partner
support is thought to be an important determinant for
uptake and outcomes of PMTCT initiatives [9–11],
follow up of our cohort of mothers with and without
partners will add to the evidence on the impact of male
partner involvement approaches on PMTCT services.
According to Malawi’s demographic health survey, 14%
of Malawian women are married to a man with more than
one wife. Polygamy is most common in the Northern
Region [12], which may explain why we found a lower
proportion of women in polygamous marriage (9%). In
Table 2 Number of facility staff trained in study procedures and good clinical practices
Arm and facility name ART/PMTC coordinators ART/PMTCT providers HTC providers ART clerks Total
Arm 1: Standard
Mulanje District Hospital 3 7 3 2 15
Daeyang Luke Hospital Public 2 7 3 1 13
Mwanza District Hospital 1 2 3
Mimosa Dispensary 2 2 2 6
Kasinje Health Centre 4 2 2 8
Dr. David Livingstone Memorial Clinic 6 1 7
Chirimba Health Centre 2 6 2 8
Arm 2: Facility Support
Muloza Health Centre 3 4 2 9
Makhetha Health Centre 1 13 1 15
Mbiza Health Centre 1 4 2 2 9
Masenjere Health Centre 2 4 6
Mdeka Health Centre 4 6 2 2 14
Lobi Rural Hospital 3 2 5
Kadidi Health Centre 7 7
Arm 3: Community Support
Mulanje Mission Hospital 1 8 3 2 14
Trinity Mission Hospital 5 10 15
Mulomba Health Centre 2 4 1 7
Mpala health Centre 1 3 2 2 8
Biriwiri Health Centre 3 3 2 8
Nsipe Health Centre 4 2 1 7
Bilira Health Center 3 2 2 7
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our study, 98% of pregnant and lactating women were re-
ported clinically asymptomatic. This high proportion of
women starting ART in the earliest stages is an indication
of the success of Malawi’s PMTCT programming.
Malawi, as the first country to implement Option B+,
has the potential to be a leader in developing and docu-
menting highly effective models of service delivery to
pregnant and lactating women and enhance retention in
lifelong care and treatment. Cluster randomized con-
trolled trials are needed to determine whether promising
interventions are indeed effective. However, the imple-
mentation of such trials pose a substantial challenge, es-
pecially across multiple regions, different facility types,
and several implementing partners. Thus, the ability to
select 21 comparable clinics, stratify them in a meaning-
ful way, and have each enroll its target sample size is an
achievement. This achievement stems from clear leader-
ship, small incentives to clinical staff, and well-
coordinated teams.
This paper described the processes for site selection,
recruitment, and enrollment of study participants, along
with baseline characteristics of study sites and women
enrolled in the trial. Follow-up of participants was com-
pleted on July 31st, 2016. The final results and outcomes
(per protocol) of this study are reported elsewhere [13].
Alongside this trial, a qualitative study has been imple-
mented to explore experiences of patients and health
care workers in relation to the implementation of
Option B+ and the trial interventions [14].
Limitations
We were not able to report the precise number of
women who refused to participate in the study, as
this data was not collected consistently across the
sites. However, compared to facility cohort data, it
appears that we were able to enroll the majority of
eligible women.
Conclusions
Malawi, as the first country to implement Option B+,
has the potential to be a leader in developing and docu-
menting highly effective models of service delivery to
Table 4 Facility characteristics during enrollment period
Arm and facility name Enrolment
duration
in weeks
HIV test kit
stockout in
weeks
HTC service
NOT available
in weeks
Number of days
per week ANC
provided
Number of days
per week ART
provided
ART provided
at ANC (Yes/No)
Arm 1: Standard
Mulanje District Hospital 31 - - 5 5 Yes
Daeyang Luke Hospital Public 36 - - 4 5 Yes
Mwanza District Hospital 33 2 2 5 5 Yes
Mimosa Dispensary 26 - 4 2 1 Yes
Kasinje Health Centre 33 - 1 5 4 Yes
Dr. David Livingstone Memorial Clinic 51 - 4 5 5 No
Chirimba Health Centre 27 - - 4 1 Yes
Arm 2: Facility Support
Muloza Health Centre 27 4 4 3 1 Yes
Makhetha Health Centre 31 8 8 3 1 No
Mbiza health Centre 29 - - 2 1 Yes
Masenjere Health Centre 27 8 8 2 2 Yes
Mdeka Health centre 24 2 2 2 1 Yes
Lobi Rural Hospital 36 - - 5 5 Yes
Kadidi Health Center 17 2 2 2 1 Yes
Arm 3: Community Support
Mulanje Mission Hospital 38 - - 5 5 Yes
Trinity Mission Hospital 43 4 4 5 5 Yes
Mulomba Health Centre 29 - 4 2 1 Yes
Mpala health Centre 29 - - 3 1 Yes
Biriwiri Health Centre 35 2 3 3 1 Yes
Nsipe Health Centre 29 - - 3 1 Yes
Bilira Health Center 34 2 2 3 1 Yes
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Table 5 Cumulative Baseline characteristics of women included in the study
Total Percent Pregnant Percent Lactating Percent P- value (Chi-square)
N 1269 1094 86% 175 14%
Health Zone
Central West 272 21% 223 20% 49 28% 0.07
South East 585 46% 512 47% 73 42%
South West 412 32% 359 33% 53 30%
Age
15–21 266 21% 224 20% 42 24% 0.30
22–28 488 38% 419 38% 69 39%
29–35 406 32% 355 32% 51 29%
> 36 103 8% 94 9% 9 5%
Missing 6 0.5% 2 0.2% 4 2%
Months pre- or postnatal at enrolment
< 3 months 370 34% 42 24%
3–6 months 582 53% 22 13%
> 6 months 47 4% 51 29%
Missing 97 9% 61 35%
WHO Stage at ART initiation
Stage 1 (asymptomatic) 1211 95% 1044 95% 167 95% 0.12
Stage 2 13 1% 13 1%
Stage 3 10 1% 7 1% 3 2%
Stage 4 - - -
Missing 35 3% 30 3% 5 3%
Marital Status
Never married 21 2% 16 1% 5 3% 0.001
Maried Monogamous 1068 84% 942 86% 124 71%
Maried Polygamous 110 9% 96 9% 13 7%
Divorced 49 4% 27 2% 22 13%
Widowed 17 1% 7 1% 10 6%
Missing 7 1% 6 1% 1 1%
Currently having a sexual partner
Yes 1193 94% 1053 96% 140 80% 0.001
No 60 5% 29 3% 31 18%
Missing 16 r
1%
12 r
1%
4 2%
Current sexual partner living in catchment area
Yes 994 83% 878 83% 116 83% 0.43
No 133 11% 118 11% 14 10%
Missing 66 6% 57 5% 10 7%
Enrollment period
01Oct-31Dec’13 108 9% 94 9% 14 8% 0.67
01lan-31Mar’14 551 43% 468 43% 83 47%
01Apr-30Jun’14 417 33% 362 33% 55 31%
01lul -30Sep’14 186 15% 163 15% 23 13%
01Oct-31Dec’14 7 1% 7 1%
Follow up time from Enrolment to Study End
20–23 months 47 4% 40 4% 7 4% 0.37
24–27 months 467 37% 411 38% 56 32%
28–32 months 755 59% 643 59% 112 64%
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provide needed support to women and enhance reten-
tion in lifelong HIV care and treatment approaches. The
PURE trial is expected to play a critical role in this
process. We show that a consortium of organizations
was successful in recruiting a complex cohort of preg-
nant and lactating women across 3 geographical zones
in Malawi within a reasonable timeline.
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